chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Activated partial thromboplastin time prolonged, Alanine aminotransferase normal, Anion gap, Aspartate aminotransferase increased, Atrial fibrillation
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Atrial flutter, Basophil count decreased, Basophil percentage decreased, Blood albumin decreased, Blood alkaline phosphatase normal
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Blood bilirubin normal, Blood calcium decreased, Blood chloride decreased, Blood creatine phosphokinase increased, Blood creatinine normal
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Blood glucose normal, Blood potassium normal, Blood sodium decreased, Blood urea normal, Brain natriuretic peptide increased
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Breath sounds abnormal, COVID-19, Carbon dioxide normal, Chest X-ray abnormal, Chest discomfort
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Colitis ulcerative, Constipation, Dehydration, Depression
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Electrocardiogram abnormal, Eosinophil count decreased, Eosinophil percentage decreased, Glomerular filtration rate normal, Granulocyte count
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Granulocyte percentage increased, Haematocrit decreased, Haemoglobin decreased, Hyperglycaemia, Influenza A virus test negative
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Influenza B virus test, Insomnia, International normalised ratio increased, Iron deficiency anaemia, Laboratory test
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphocyte count decreased, Lymphocyte percentage decreased, Malaise, Mean cell haemoglobin concentration normal, Mean cell haemoglobin increased
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Mean cell volume increased, Mean platelet volume decreased, Monocyte count increased, Monocyte percentage increased, Nasal congestion
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Obesity, Pharyngeal exudate, Platelet count normal, Pneumonia, Pneumonia bacterial
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Productive cough, Protein total normal, Prothrombin time prolonged, Red blood cell count decreased, Red cell distribution width normal
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Respiratory symptom, Respiratory syncytial virus test negative, Respiratory tract congestion, Rhinorrhoea, SARS-CoV-2 test positive
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Troponin I normal, Troponin normal, Type 2 diabetes mellitus, Upper respiratory tract infection, Upper-airway cough syndrome
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Wheezing, White blood cell count normal
Clinical narrative: Narrative:  1/13/23 at 17:09 - Pt presented to ED with left chest pressure, productive cough, and congestion x 1 week. Pt also reporting 5 days of malaise, intermittent chills, some wheezing, some runny nose, and postnasal drip. Pt tested COVID positive while in ED. Differential diagnosis includes occult coronary syndrome pneumonia COVID-19 Troponin unremarkable EKG shows A. fib which is chronic in nature no STEMI BNP slightly elevated at 336 creatinine normal Elevated CPK Sodium low at 128 most likely due to dehydration Lab COVID-19 positive Chest x-ray shows right lung pneumonia While in ED, Pt received now dose of oxymetazoline nasal spray, Solumedrol 125mg IVP, albuterol inhalation, guaifenesin 400mg, ceftriaxone 1 gm IV and now dose of azithromycin 500mg IV. Pt admitted 1/13 for community-acquired pneumonia and remained inpatient until 1/16/23. Pt admitted to medical floor d/t COVID+ diagnosis and CXR revealed RLL pneumonia - multiple comorbid conditions and concern for respiratory decompensation. Principal diagnosis (reason for admission after study) = Acute community acquired bacterial pneumonia of the right lower lobe. Additional diagnosis included: COVID, chronic afib/a-flutter, ulcerative colitis, Type II DM with hyperglycemia. depression/insomnia, constipation, elevated CPK, and IDA. HOSPITAL COURSE: Patient admitted to SDU for initial treatment of acute bacterial community acquired pneumonia. Patient responded well to IV ceftriaxone and azithromycin for 3 days. Patient did not meet inpatient criteria for the treatment of Covid 19. At the time of discharge URI symptoms that patient had presented with had improved. Patient was subsequently discharged with a 10 day course of doxycycline and was instructed to follow up with his pcp in 1-2 weeks. return to the ED for any worsening shortness of breath, chest pain, orthopnea, swelling or near syncope.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Investigation, Lymphadenopathy, Pain, Weight
Clinical narrative: she could feel it on left side of chest; Had Lymph node swelling; Had Lymph node swelling and pain there; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A 73-year-old female patient received BNT162b2 (BNT162B2), on 18Mar2021 as dose 1, single (Lot number: EN6306) at the age of 71 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Lyme infection", start date: 2020 (unspecified if ongoing); "mild stroke", start date: 2020 (unspecified if ongoing); "cellulitis" (unspecified if ongoing); "AFIB" (unspecified if ongoing); "allergic to a lot of antibiotics" (unspecified if ongoing); "cough" (unspecified if ongoing); "sinus" (unspecified if ongoing); "congestion" (unspecified if ongoing). Concomitant medication(s) included: CORICIDIN HBP COUGH AND COLD taken for cough, sinus disorder, nasal congestion; ATENOLOL taken for cerebrovascular accident.  The following information was reported: CHEST PAIN (non-serious), outcome "recovering", described as "she could feel it on left side of chest"; LYMPHADENOPATHY (non-serious), outcome "recovered", described as "Had Lymph node swelling"; PAIN (non-serious), outcome "recovered", described as "Had Lymph node swelling and pain there". Relevant laboratory tests and procedures are available in the appropriate section.
Age: 2.0
Sex: F
Vaccine: DTAPIPVHIB, PNC15
Symptoms: Seizure
Clinical narrative: seizure; Information has been received from the FDA (VAERS ID 2122934) on 01-DEC-2022.  This spontaneous report as received from a health professional who refers to a 2-year-old White female patient. The patient's medical history, concurrent conditions, and concomitant therapies were not reported.  On 16-FEB-2022 at 14:15, the patient was vaccinated with a dose of pneumococcal 15v conj vaccine (crm197) (VAXNEUVANCE) injection, administered for prophylaxis (dose, strength, lot #, expiry date, and route of administration were not provided); and diphtheria vaccine toxoid, hib vaccine conj (tet tox), pertussis vaccine acellular 5-component, polio vaccine inact 3v (mrc 5), tetanus vaccine toxoid (PENTACEL) (strength, formulation, lot #, expiry date, route of administration, and indication were not provided).  On 17-FEB-2022, the patient experienced seizure. The event lasted for 1 minute, and then, the patient recovered from the event of seizure on that day. She was sent to the emergency department for observation.  The causal relationship between seizure, pneumococcal 15v conj vaccine (crm197) (VAXNEUVANCE) and diphtheria vaccine toxoid, hib vaccine conj (tet tox), pertussis vaccine acellular 5-component, polio vaccine inact 3v (mrc 5), tetanus vaccine toxoid (PENTACEL) was unknown.  The reporter considered seizure to be a medically significant adverse event.  Follow up information has been received on 17-JAN-2023, via a telephone call performed and the front office staff who stated "without a patient name or date of birth, they would not be able to provide any information."
Sex: F
Vaccine: COVID19
Symptoms: Autoimmune disorder, Eye inflammation, Inflammation
Clinical narrative: stress out the autoimmune system; inflammation in my eyes; inflammation; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 61-year-old female patient received BNT162b2 (BNT162B2), on 17Oct2021 as dose 3 (booster), single (Lot number: FF2590) for covid-19 immunisation. The patient's relevant medical history included: "auto immune disorder" (ongoing), notes: I do have an auto immune disorder; "I'm celiac person" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (first on 11Mar2021 - Lot # EN6208), administration date: 11Mar2021, for COVID-19 immunization, reaction(s): "stress out the autoimmune system", "inflammation", "inflammation in my eyes to come down"; BNT162b2 (second dose 01Apr2021 - Lot# ER7734), administration date: 01Apr2021, for COVID-19 immunization.  The following information was reported: AUTOIMMUNE DISORDER (medically significant), outcome "unknown", described as "stress out the autoimmune system"; EYE INFLAMMATION (non-serious), outcome "unknown", described as "inflammation in my eyes"; INFLAMMATION (non-serious), outcome "unknown". The events "inflammation in my eyes" and "inflammation" required physician office visit.  Clinical course: Patient stated that, she wanted to know how the COVID vaccine could stress out the autoimmune system and we can have some inflammation as a result of that. She had some inflammation in her eyes to come down. Patient need information for both [Pfizer monovalent and bivalent vaccines] because her first reaction was from the initial vaccine and then she had reactions to the booster as well. Patient reported that she do have an auto immune disorder already and she was celiac person, she had other things go on but mainly the thing she can't seem to, she was having a hard time figuring out was this inflammation and the only thing that can come down to was that it might be a reaction to the COVID vaccine.
Age: 85.0
Sex: M
Vaccine: COVID19-2, COVID19-2
Symptoms: Acute respiratory failure, Agitation, Aspiration, Behaviour disorder, Blood culture negative
Clinical narrative: Prior VAERS submitted #929214 COVID+ 1/16/23.  Vaccination Status- pfizer x3 + Pfizer BIVALENT x1 Expand All Collapse All BRIEF OVERVIEW: Discharge Provider: MD Primary Care Provider: DO Admission Date: 1/16/2023 Discharge Date: Jan 19, 2023   Active Hospital Problems   Diagnosis Date Noted POA ? Unspecified severe protein-calorie malnutrition 01/17/2023 Unknown ? Community acquired pneumonia, unspecified laterality   DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Community acquired pneumonia, unspecified laterality [J18.9] Sepsis with acute organ dysfunction without septic shock, due to unspecified organism, unspecified type [A41.9, R65.20] COVID-19 [U07.1]   HOSPITAL COURSE: 85yom pmhx LBD with Parkinsonism, dysphagia s/p G tube placement, prostate cancer on oral chemotherapy who was admitted for management of sepsis secondary to community acquired pneumonia. Reportedly started on Robinul several days prior to presentation and noted to have become increasingly lethargic and weak, with inability to clear secretions. Notably Covid19+ but suspected viral shedding from previous infection one month prior. He was treated with ceftriaxone and azithromycin and symptoms did improve over time. He was mildly hypoxic on presentation, corrected with 2L NC, and tachycardic 140-150s sinus corrected with sepsis bolus. Through his course his oxygen requirements improved but continued to have difficulty mobilizing thick secretions. Also developed mild fluid overload from resuscitation. Improved significantly with several doses of IV lasix. By day 4 he was off oxygen and mentation, activity, and sputum output had improved significantly. Wife was looking into hospice facilities prior to admission. She, along with her son, met with social work and hospice to discuss options for home hospice. Home hospice was set up and patient was discharged 1/19/23 in stable condition, with completion of 5 day course of antibiotics, transitioned from ceftriaxone and azithro IV to oral Augmentin for 1 additional day. Robinul discontinued and listed as allergy given severe AMS.
Age: 85.0
Sex: M
Vaccine: COVID19-2, COVID19-2
Symptoms: COVID-19, Chest X-ray normal, Confusional state, Dementia, Gastrointestinal tube insertion
Clinical narrative: Prior VAERS submitted #929214 COVID+ 1/16/23.  Vaccination Status- pfizer x3 + Pfizer BIVALENT x1 Expand All Collapse All BRIEF OVERVIEW: Discharge Provider: MD Primary Care Provider: DO Admission Date: 1/16/2023 Discharge Date: Jan 19, 2023   Active Hospital Problems   Diagnosis Date Noted POA ? Unspecified severe protein-calorie malnutrition 01/17/2023 Unknown ? Community acquired pneumonia, unspecified laterality   DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Community acquired pneumonia, unspecified laterality [J18.9] Sepsis with acute organ dysfunction without septic shock, due to unspecified organism, unspecified type [A41.9, R65.20] COVID-19 [U07.1]   HOSPITAL COURSE: 85yom pmhx LBD with Parkinsonism, dysphagia s/p G tube placement, prostate cancer on oral chemotherapy who was admitted for management of sepsis secondary to community acquired pneumonia. Reportedly started on Robinul several days prior to presentation and noted to have become increasingly lethargic and weak, with inability to clear secretions. Notably Covid19+ but suspected viral shedding from previous infection one month prior. He was treated with ceftriaxone and azithromycin and symptoms did improve over time. He was mildly hypoxic on presentation, corrected with 2L NC, and tachycardic 140-150s sinus corrected with sepsis bolus. Through his course his oxygen requirements improved but continued to have difficulty mobilizing thick secretions. Also developed mild fluid overload from resuscitation. Improved significantly with several doses of IV lasix. By day 4 he was off oxygen and mentation, activity, and sputum output had improved significantly. Wife was looking into hospice facilities prior to admission. She, along with her son, met with social work and hospice to discuss options for home hospice. Home hospice was set up and patient was discharged 1/19/23 in stable condition, with completion of 5 day course of antibiotics, transitioned from ceftriaxone and azithro IV to oral Augmentin for 1 additional day. Robinul discontinued and listed as allergy given severe AMS.
Age: 85.0
Sex: M
Vaccine: COVID19-2, COVID19-2
Symptoms: Hypoxia, Swallow study abnormal
Clinical narrative: Prior VAERS submitted #929214 COVID+ 1/16/23.  Vaccination Status- pfizer x3 + Pfizer BIVALENT x1 Expand All Collapse All BRIEF OVERVIEW: Discharge Provider: MD Primary Care Provider: DO Admission Date: 1/16/2023 Discharge Date: Jan 19, 2023   Active Hospital Problems   Diagnosis Date Noted POA ? Unspecified severe protein-calorie malnutrition 01/17/2023 Unknown ? Community acquired pneumonia, unspecified laterality   DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Community acquired pneumonia, unspecified laterality [J18.9] Sepsis with acute organ dysfunction without septic shock, due to unspecified organism, unspecified type [A41.9, R65.20] COVID-19 [U07.1]   HOSPITAL COURSE: 85yom pmhx LBD with Parkinsonism, dysphagia s/p G tube placement, prostate cancer on oral chemotherapy who was admitted for management of sepsis secondary to community acquired pneumonia. Reportedly started on Robinul several days prior to presentation and noted to have become increasingly lethargic and weak, with inability to clear secretions. Notably Covid19+ but suspected viral shedding from previous infection one month prior. He was treated with ceftriaxone and azithromycin and symptoms did improve over time. He was mildly hypoxic on presentation, corrected with 2L NC, and tachycardic 140-150s sinus corrected with sepsis bolus. Through his course his oxygen requirements improved but continued to have difficulty mobilizing thick secretions. Also developed mild fluid overload from resuscitation. Improved significantly with several doses of IV lasix. By day 4 he was off oxygen and mentation, activity, and sputum output had improved significantly. Wife was looking into hospice facilities prior to admission. She, along with her son, met with social work and hospice to discuss options for home hospice. Home hospice was set up and patient was discharged 1/19/23 in stable condition, with completion of 5 day course of antibiotics, transitioned from ceftriaxone and azithro IV to oral Augmentin for 1 additional day. Robinul discontinued and listed as allergy given severe AMS.
Age: 85.0
Sex: M
Vaccine: COVID19-2, COVID19-2
Symptoms: Asthenia, COVID-19, Condition aggravated, Cough, Drug hypersensitivity
Clinical narrative: Prior VAERS submitted #929214 COVID+ 1/16/23.  Vaccination Status- pfizer x3 + Pfizer BIVALENT x1 Expand All Collapse All BRIEF OVERVIEW: Discharge Provider: MD Primary Care Provider: DO Admission Date: 1/16/2023 Discharge Date: Jan 19, 2023   Active Hospital Problems   Diagnosis Date Noted POA ? Unspecified severe protein-calorie malnutrition 01/17/2023 Unknown ? Community acquired pneumonia, unspecified laterality   DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Community acquired pneumonia, unspecified laterality [J18.9] Sepsis with acute organ dysfunction without septic shock, due to unspecified organism, unspecified type [A41.9, R65.20] COVID-19 [U07.1]   HOSPITAL COURSE: 85yom pmhx LBD with Parkinsonism, dysphagia s/p G tube placement, prostate cancer on oral chemotherapy who was admitted for management of sepsis secondary to community acquired pneumonia. Reportedly started on Robinul several days prior to presentation and noted to have become increasingly lethargic and weak, with inability to clear secretions. Notably Covid19+ but suspected viral shedding from previous infection one month prior. He was treated with ceftriaxone and azithromycin and symptoms did improve over time. He was mildly hypoxic on presentation, corrected with 2L NC, and tachycardic 140-150s sinus corrected with sepsis bolus. Through his course his oxygen requirements improved but continued to have difficulty mobilizing thick secretions. Also developed mild fluid overload from resuscitation. Improved significantly with several doses of IV lasix. By day 4 he was off oxygen and mentation, activity, and sputum output had improved significantly. Wife was looking into hospice facilities prior to admission. She, along with her son, met with social work and hospice to discuss options for home hospice. Home hospice was set up and patient was discharged 1/19/23 in stable condition, with completion of 5 day course of antibiotics, transitioned from ceftriaxone and azithro IV to oral Augmentin for 1 additional day. Robinul discontinued and listed as allergy given severe AMS.